» Articles » PMID: 15577414

A Randomized Controlled Trial of 5% Lidocaine Gel for HIV-associated Distal Symmetric Polyneuropathy

Overview
Date 2004 Dec 4
PMID 15577414
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the analgesic efficacy and safety of 5% lidocaine gel in painful HIV-associated distal sensory polyneuropathy (DSP).

Background: Painful DSP, the most common neurologic complication in HIV infection, is difficult to treat. Lidocaine 5% gel was effective in alleviating neuropathic pain in an open-label study of HIV DSP.

Methods: In a double-blind, placebo-controlled, crossover, multi-center study, 64 subjects were randomized to receive 5% lidocaine or vehicle gel for 2 weeks (phase A). A washout period of 2 weeks was followed by a crossover to the alternate agent for another 2 weeks (phase B). The primary outcome was difference in average pain scores (Gracely pain scale) between the 2 groups during the second week of each treatment period. Secondary outcomes included differential effect of the first treatment, difference in global pain relief, and pain response by neurotoxin exposure.

Results: The baseline pain scores of the 2 groups were similar. The average pain scores during the second week of each phase of the lidocaine gel group did not differ from those of the placebo group (phase A: lidocaine 1.09, placebo 1.15; phase B: lidocaine 1.16, placebo 1.10). There also was no difference noted in secondary outcomes. The pain responses of lidocaine gel-treated subjects with current exposure to neurotoxic antiretrovirals (1.18) did not differ compared with those without (1.10) (P = 0.358). There were no significant adverse effects.

Conclusion: Lidocaine 5% gel is a safe but ineffective agent in the treatment of pain in HIV-associated DSP.

Citing Articles

Neuropathy in Human Immunodeficiency Virus: A Review of the Underlying Pathogenesis and Treatment.

Motwani L, Asif N, Patel A, Vedantam D, Poman D Cureus. 2022; 14(6):e25905.

PMID: 35844323 PMC: 9278792. DOI: 10.7759/cureus.25905.


Pharmacologic and Non-Pharmacologic Treatments for Chronic Pain Used by Patients with Pain, HIV, and Depression.

Uebelacker L, Cherenack E, Busch A, Baker J, Pinkston M, Gleason N AIDS Behav. 2021; 26(3):864-873.

PMID: 34468967 PMC: 9125741. DOI: 10.1007/s10461-021-03447-x.


Traditional Chinese Medicine and Human Immunodeficiency Virus-Associated Neuropathy.

Anastasi J, Chang M, Capili B, Dawes N J Chin Med. 2021; 95:16-20.

PMID: 34017151 PMC: 8132577.


Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis.

Amaniti A, Sardeli C, Fyntanidou V, Papakonstantinou P, Dalakakis I, Mylonas A Medicina (Kaunas). 2019; 55(12).

PMID: 31795171 PMC: 6956009. DOI: 10.3390/medicina55120762.


Update of HIV-Associated Sensory Neuropathies.

Aziz-Donnelly A, Harrison T Curr Treat Options Neurol. 2017; 19(10):36.

PMID: 28861848 DOI: 10.1007/s11940-017-0472-3.